SFCE METRO‐01 four‐drug metronomic regimen phase II trial for pediatric extracranial tumor
Résumé
To investigate the antitumor activity of a four-drug metronomic chemotherapy (MC) regimen in relapsed/progressing pediatric extracranial solid tumors (EST). The primary objective was clinical benefit (complete response /partial response/stable disease [SD]) after two cycles of therapy (four months).